Chronic Lymphocytic Leukemia (CLL): Symptoms (ex. Skin Blisters), Diagnosis and Treatment (Vit D?)

Summary

This video provides a comprehensive overview of chronic lymphocytic leukemia (CLL), a blood cancer affecting mature B lymphocytes. It explains the epidemiology, highlighting that CLL is most common in older adults, particularly males and Caucasians. The lesson covers clinical features such as lymphadenopathy, splenomegaly, hepatomegaly, constitutional symptoms, skin involvement, and blood abnormalities like anemia and thrombocytopenia. Diagnosis relies on flow cytometry and distinguishing CLL from small lymphocytic lymphoma. Staging systems and treatment approaches are discussed, emphasizing a 'watch and wait' strategy for asymptomatic patients, with treatment options guided by genetic mutations. Vitamin D and calcium supplementation may slow disease progression.

Takeaways

• 🧬 CLL (Chronic Lymphocytic Leukemia) is a blood cancer involving mature B-lymphocytes and is closely related to Small Lymphocytic Lymphoma (SLL), distinguished mainly by whether blood or lymph nodes are primarily involved.
• 📊 CLL is the most common adult leukemia in Western countries, typically affecting older adults with a median age of 70, and is slightly more common in males and Caucasians.
• 🔬 CLL is often an incidental finding on routine CBCs, showing elevated lymphocyte counts and mature lymphocytes on blood smear.
• 🩺 Physical findings may include lymphadenopathy (50–90%), splenomegaly (25–55%), hepatomegaly (15–25%), as well as less common symptoms like constitutional signs (weight loss, fever, night sweats) and skin involvement (leukemia cutis).
• 💉 Laboratory abnormalities can include anemia, neutropenia, thrombocytopenia, and, in severe cases, hyperviscosity syndrome causing headaches or strokes.
• ✅ Diagnosis of CLL requires a B-lymphocyte count >5,000/μL and monoclonal B cells positive for CD5, CD19, CD20, and CD23; SLL requires <5,000/μL and lymph node involvement.
• 📏 Staging uses the Rai system (0–4), where higher stages indicate involvement of lymph nodes, liver, spleen, anemia, and thrombocytopenia.
• ⏳ Asymptomatic patients are managed with a 'watch and wait' approach, as early treatment does not improve survival and may cause unnecessary side effects.
• 💊 Symptomatic patients are treated based on genetic markers: 17p deletion/TP53 mutation or IGHV mutation status guides the choice of targeted therapy or chemotherapy regimens.
• 🌞 Supportive care with vitamin D and calcium supplementation may slow the progression of CLL.
• 📈 Prognosis varies: early-stage, asymptomatic patients may have a median survival of 10+ years, while progressive symptomatic disease has a median survival of 18 months to 3 years.
• 🧠 Key exam point: differentiate CLL from SLL using lymphocyte count and lymph node involvement, and remember 'do no harm' for asymptomatic patients.

Q & A

What type of cancer is Chronic Lymphocytic Leukemia (CLL)?

CLL is a blood cancer involving mature B lymphocytes that progressively accumulate over time. It is considered a type of leukemia because it primarily affects the blood.

How is CLL distinguished from small lymphocytic lymphoma (SLL)?

CLL is diagnosed when there are more than 5,000 monoclonal B lymphocytes per microliter in the blood, with or without lymph node involvement. SLL is diagnosed when lymph node involvement is present but the B lymphocyte count is below 5,000 per microliter.

What is the typical epidemiology of CLL?

CLL is the most common adult leukemia in Western countries, more common in males (male-to-female ratio 1.3–1.7:1), typically diagnosed around age 70, more frequent in Caucasians, and may have a genetic predisposition or associations with certain exposures like benzene, though no definitive cause is proven.

What are the most common physical findings in patients with CLL?

The most common findings are lymphadenopathy (50–90% of cases, usually cervical, axillary, or supraclavicular), splenomegaly (25–55% of cases), and hepatomegaly (15–25% of cases). Lymph nodes and organs are usually firm, painless, and non-tender.

What constitutional symptoms might occur in CLL, and how common are they?

Constitutional symptoms, which occur in 5–10% of cases, include unintentional weight loss (>10% in 6 months), fevers (>38°C or 100.5°F for over 2 weeks), drenching night sweats, and extreme fatigue.

What less common manifestations can occur due to CLL?

Less common findings include leukemia cutis (skin infiltration with lesions, ulcers, or blisters), exaggerated reactions to insect bites, renal involvement (e.g., membranoproliferative glomerulonephritis), and hyperviscosity syndrome due to very high lymphocyte counts, potentially causing headaches, transient ischemic attacks, or strokes.

How is CLL diagnosed through blood work?

Diagnosis requires flow cytometry showing an absolute B lymphocyte count greater than 5,000 per microliter with monoclonal B cells positive for CD5, CD19, CD20, and CD23.

What are the main stages of CLL using the modified Rai system?

Rai staging is: Stage 0—lymphocytosis only; Stage 1—lymphocytosis with lymphadenopathy; Stage 2—lymphocytosis with splenomegaly or hepatomegaly; Stage 3—lymphocytosis with anemia; Stage 4—lymphocytosis with thrombocytopenia, possibly with anemia, splenomegaly, or lymphadenopathy.

What is the standard initial management approach for asymptomatic CLL patients?

For asymptomatic patients, a 'watch-and-wait' approach is recommended. Immediate treatment is unnecessary as survival rates are similar to the general population, and unnecessary treatment could expose patients to chemotherapy risks.

How is treatment decided for symptomatic CLL patients?

Treatment depends on genetic testing: patients with 17p deletion or TP53 mutation are treated with a Bruton's tyrosine kinase inhibitor (BTKi) plus or minus a CD20 antibody (rituximab). Younger patients without these mutations may receive FCR (fludarabine, cyclophosphamide, rituximab) or BTKi plus rituximab, depending on IGHV mutation status. Vitamin D and calcium supplements may help reduce disease progression.

What is the prognosis of CLL based on symptom severity and stage?

Early-stage symptomatic CLL has a median survival of over 10 years, while progressive disease with lymphadenopathy, anemia, or thrombocytopenia has a median survival of 18 months to 3 years.